Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Adil Daud

1-50 of 135 results

View this query on the Wikidata Query Service
Pembrolizumab versus Ipilimumab in Advanced Melanoma

scientific article (publication date: 25 June 2015)
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

scientific article (publication date: 11 July 2013)
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

scientific article
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

scientific article (publication date: 20 September 2014)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

scientific article
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

scientific article
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

scientific article published on April 2016
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

scientific article
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity

scientific article
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma

scientific article
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

scientific article published on 14 May 2015
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

scientific article published on 07 March 2016
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

scientific article
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

scientific article published on 31 October 2016
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

scientific article
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

scientific article
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

scientific article
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

scientific article published on 29 September 2008
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

scientific article
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments

scientific article published on 25 June 2018
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

scientific article published on 15 July 2014
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

scientific article published on 29 July 2015
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

scientific article published on December 2008
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

scientific article
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

scientific article published on 17 August 2016
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

scientific article
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

scientific article published on 08 September 2009
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

scientific article
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

scientific article
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

scientific article published on 28 December 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.

scientific article published on 14 April 2017
Melanoma, version 2.2013: featured updates to the NCCN guidelines

scientific article published in April 2013
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

scientific article published on 9 October 2017
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor

scientific article published on 01 July 2008
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

scientific article published on 21 March 2017
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

scientific article
Nivolumab plus ipilimumab in the treatment of advanced melanoma.

scientific article published on 31 October 2015
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

scientific article published on 18 November 2014
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma

scientific article
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies

scientific article
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

scientific article
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

scientific article
Cutaneous melanoma: prognostic factors

scientific article
Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma

scientific article published on October 1, 2010
Activated Stat-3 in Melanoma

scientific article published on 01 July 2008
Melanoma, Version 4.2014

scientific article published on May 1, 2014
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

scientific article
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

scientific article
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies

scientific article
Treatment of cutaneous melanoma: current approaches and future prospects.

scientific article

Paulina is supported by:

About Paulina

Help